GOSH and Oliver Patch in cancer research partnership with Innovative Trials
Globally 400,000 children are impacted every year by cancers that include leukaemia and lymphoma
Read More
Tag: leukaemia
Glasgow scientists develop first bone marrow model to support human stem cells
LT-HSCs replenish blood cells after treatment for blood cancers, such as leukaemia
Read More
Storm reveals STC-15 data for patients with acute myeloid leukaemia
Data shows that STC-15 exhibits efficacy as a single agent and in combination with venetoclax
Read More
First patients enrolled for Priothera’s mocravimod trial
Treatment is a maintenance therapy for certain patients with acute myeloid leukaemia
Read More
Recommendation for Novartis’ chronic myeloid leukaemia STAMP inhibitor
Chronic myeloid leukaemia therapy Scemblix receives NICE final draft recommendation in Britain
Read More
Takeda’s blood cancer drug fails to achieve Phase III endpoint
Pevonedistat plus azacitidine did not meet primary endpoint of EFS
Read More
NICE recommendation for MSD’s Prevymis after re-evaluation
Prevymis is a member of a new class of drugs called non-nucleoside CMV inhibitors.
Read More
Trial results show promise for chemo-free future treatment
95% of those treated in the study were found to have a complete remission rate.
Read More
SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma
Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting.
Read More
First children set to receive Novartis’ Kymriah
The first children to receive Novartis’ Kymriah – a ‘game-changing’ CAR-T therapy for cancer – will start treatment at Great Ormond Street Hospital in London this week, NHS England has announced.
Read More
NHS England strikes deal with Novartis on Kymriah
Hospitals are gearing up to offer Novartis’ ground-breaking CAR-T therapy Kymriah to children with advanced leukaemia, after the drugmaker reached a deal with NHS England over its provision.
Read More
EU expands use of Amgen’s Blincyto
European regulators have expanded the scope of Amgen’s Blincyto to include the treatment of younger patients with a rare type of leukaemia.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
